2024
Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis
Venkat R, Redd R, Harris A, Aryee M, Marneth A, Kamaz B, Kim C, Wazir M, Weeks L, Stahl M, DeAngelo D, Lindsley R, Luskin M, Hobbs G, How J. Risk of bleeding in patients with essential thrombocythemia and extreme thrombocytosis. Blood Advances 2024, 8: 6043-6054. PMID: 39293089, PMCID: PMC11635702, DOI: 10.1182/bloodadvances.2024013777.Peer-Reviewed Original ResearchConceptsRisk of bleedingClinically relevant nonmajor bleedingEssential thrombocythemiaBleeding riskPlatelet countCumulative incidenceDana-Farber Cancer Institute and Massachusetts General HospitalAssociated with acquired von Willebrand syndromeCumulative incidence of thrombosisCumulative incidence of bleedingIncreased bleeding riskIncidence of bleedingReduced bleeding riskVon Willebrand syndromeIncidence of thrombosisNonmajor bleedingDNMT3A mutationsMassachusetts General HospitalThrombotic eventsDana-FarberDiabetes mellitusBleedingPatientsRisk factorsTreatment decisions
2021
A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE)
Konkle B, Quon D, Raffini L, Recht M, Radulescu V, Carpenter S, Dunn A, Lu M, Watt M. A Prospective Observational Study of Antihemophilic Factor (Recombinant) Prophylaxis Related to Physical Activity Levels in Patients with Hemophilia A in the United States (SPACE). Journal Of Blood Medicine 2021, 12: 883-896. PMID: 34703348, PMCID: PMC8523903, DOI: 10.2147/jbm.s327180.Peer-Reviewed Original ResearchOccurrence of bleedingPhysical activity levelsPhysical activityRisk of bleedingHemophilia AFactor VIIIActivity trackersActivity levelsPhysical activity riskSevere/moderately severe hemophilia AInfusion timeIncreased risk of bleedingWearable activity trackersAnnualized bleeding rateFactor VIII prophylaxisFactor VIII inhibitorIncreased bleeding riskSevere hemophilia AObservational outcome studyProspective observational studyAntihemophilic factorInjury-relatedHealth dataBleeding riskFoundation criteria
2019
Hospitalization among Patients with Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated with Apixaban or Aspirin: Insights from the AUGUSTUS Trial
Vora A, Alexander J, Wojdyla D, Aronson R, Granger C, Darius H, Windecker S, Mehran R, Averkov O, Budaj A, Kong D, Kobalava Z, Mehta R, Mirza Z, Guimaraes P, Parkhomenko A, Quadros A, Thiele H, Goodman S, Lopes R. Hospitalization among Patients with Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated with Apixaban or Aspirin: Insights from the AUGUSTUS Trial. Circulation 2019, 140: 1960-1963. PMID: 31553201, DOI: 10.1161/circulationaha.119.043754.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsAspirinAtrial FibrillationCardiovascular AgentsCombined Modality TherapyDrug Therapy, CombinationElective Surgical ProceduresFemaleFibrinolytic AgentsHemorrhageHospitalizationHumansLength of StayMaleMiddle AgedMulticenter Studies as TopicPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsProportional Hazards ModelsProspective StudiesPurinergic P2Y Receptor AntagonistsPyrazolesPyridonesRandomized Controlled Trials as TopicSurvival AnalysisTreatment OutcomeVitamin KConceptsNon-vitamin K oral anticoagulantsAcute coronary syndromePercutaneous coronary interventionVitamin K antagonistsAtrial fibrillationOral anticoagulantsCoronary syndromePatients treated with aspirinOptimal antithrombotic therapyIncreased bleeding riskRate of bleedingComposite of deathAUGUSTUS trialRate of deathK antagonistsCombination therapyAntithrombotic therapyBleeding riskP2Y12 inhibitorsSecondary outcomesCoronary interventionRandomized treatmentAspirinPatientsApixaban
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply